Suppliers and packagers for generic pharmaceutical drug: MESNA

MESNA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Eugia Pharma	MESNA	mesna	INJECTABLE;INTRAVENOUS	220518	ANDA	Eugia US LLC	55150-520-01	1 VIAL, MULTI-DOSE in 1 BOX (55150-520-01) / 10 mL in 1 VIAL, MULTI-DOSE	2026-01-27
Fresenius Kabi Usa	MESNA	mesna	INJECTABLE;INTRAVENOUS	075811	ANDA	Fresenius Kabi USA, LLC	63323-733-10	10 VIAL, MULTI-DOSE in 1 TRAY (63323-733-10) / 10 mL in 1 VIAL, MULTI-DOSE (63323-733-01)	2001-09-05
Fresenius Kabi Usa	MESNA	mesna	INJECTABLE;INTRAVENOUS	075811	ANDA	Fresenius Kabi USA, LLC	63323-733-11	1 VIAL, MULTI-DOSE in 1 BOX (63323-733-11) / 10 mL in 1 VIAL, MULTI-DOSE	2001-09-05
Gland	MESNA	mesna	INJECTABLE;INTRAVENOUS	206992	ANDA	Gland Pharma Limited	68083-161-01	1 VIAL, MULTI-DOSE in 1 CARTON (68083-161-01) / 10 mL in 1 VIAL, MULTI-DOSE	2017-12-20
Gland	MESNA	mesna	INJECTABLE;INTRAVENOUS	206992	ANDA	Gland Pharma Limited	68083-161-10	10 VIAL, MULTI-DOSE in 1 CARTON (68083-161-10) / 10 mL in 1 VIAL, MULTI-DOSE	2017-12-20
Hikma	MESNA	mesna	INJECTABLE;INTRAVENOUS	075739	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9260-01	1 VIAL, MULTI-DOSE in 1 CARTON (0143-9260-01) / 10 mL in 1 VIAL, MULTI-DOSE	2004-02-23

Mesna Pharmaceutical Suppliers: Market Landscape and Intellectual Property

Last updated: February 19, 2026

This analysis details the global supplier landscape for mesna, a uroprotective agent used to mitigate hemorrhagic cystitis induced by certain chemotherapy regimens. It examines key manufacturers, production capacities, and the intellectual property environment surrounding mesna synthesis and formulation.

Who are the Primary Manufacturers of Mesna?

The global supply of mesna is concentrated among a limited number of pharmaceutical manufacturers. These companies are primarily responsible for the active pharmaceutical ingredient (API) synthesis and, in many cases, the finished dosage forms.

• Aurobindo Pharma: An Indian multinational pharmaceutical company with a significant presence in API manufacturing. Aurobindo has established capabilities for mesna production and supplies it to various markets.
• Baxter International: A U.S.-based healthcare company that manufactures and distributes mesna injection for hospital and clinical use. Baxter's product is often used in conjunction with cyclophosphamide and ifosfamide chemotherapy.
• Hospira (a Pfizer company): Hospira, now part of Pfizer, has historically been a supplier of generic injectable drugs, including mesna. Their operations are integrated into Pfizer's global manufacturing network.
• Medac GmbH: A German pharmaceutical company specializing in oncology supportive care. Medac is a prominent European supplier of mesna, offering both injectable and oral formulations.
• Fresenius Kabi: A global healthcare company that supplies injectable drugs, including mesna, to hospitals and clinics. Fresenius Kabi's mesna product is available in multiple markets.
• Roche: While not a primary API manufacturer of mesna for the broad market, Roche holds patents related to specific mesna formulations and combinations used in conjunction with its oncology drugs. Their involvement is more in the downstream application and patented therapeutic use.

These manufacturers operate under strict regulatory oversight from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), ensuring product quality and safety.

What are the Key Production Processes for Mesna?

The synthesis of mesna (sodium 2-mercaptoethanesulfonate) involves chemical reactions to produce the active molecule, which is then typically formulated into injectable solutions or oral powders. The primary synthesis route commonly involves the reaction of 2-chloroethanesulfonic acid with sodium hydrosulfide.

API Synthesis Steps:

1. Sulfonation/Halogenation of Ethylene: Ethylene is reacted to form a precursor such as 2-chloroethanol or vinyl chloride, which can then be functionalized to introduce the sulfonate group. Alternatively, direct sulfonation routes are employed.
2. Thiolation: The sulfonic acid derivative is then reacted with a sulfur source, such as sodium hydrosulfide (NaSH), to introduce the mercapto group (-SH). This is a critical step requiring precise control of reaction conditions to achieve high purity and yield.
3. Salt Formation: The resulting 2-mercaptoethanesulfonic acid is neutralized with a sodium base (e.g., sodium hydroxide) to form the sodium salt, mesna.
4. Purification: The crude mesna product undergoes purification steps, including crystallization, filtration, and drying, to remove impurities and achieve pharmaceutical-grade API. Common impurities can include disulfide byproducts (dimers of mesna).

Formulation:

• Injectable Solution: Mesna is typically formulated as a sterile aqueous solution for intravenous or intramuscular administration. This involves dissolving the mesna API in sterile water for injection, adjusting pH, and ensuring sterility through filtration and aseptic filling processes. Sodium bicarbonate or sodium hydroxide is often used for pH adjustment.
• Oral Powder: For oral administration, mesna API can be formulated into powders or granules, often intended for reconstitution. This may involve excipients to improve solubility, taste masking, or stability.

Manufacturers must adhere to Good Manufacturing Practices (GMP) throughout these processes. The primary challenge in mesna production lies in controlling the oxidation of the mercapto group, which can lead to the formation of the inactive dimer, 2,2'-dithiodiethane-1-sulfonate, requiring careful handling and storage.

What is the Intellectual Property Landscape for Mesna?

The intellectual property surrounding mesna is primarily focused on its therapeutic use, novel formulations, and improved synthesis methods. The basic chemical synthesis of mesna is well-established and largely off-patent.

Key Patent Areas:

• Therapeutic Use Patents: These patents cover the use of mesna in specific medical contexts, particularly for preventing or treating hemorrhagic cystitis caused by specific chemotherapeutic agents like cyclophosphamide and ifosfamide. Patents may also exist for novel combinations of mesna with other drugs.
  • Example: Patents protecting the specific dosing regimens or administration schedules of mesna in conjunction with chemotherapy.
• Formulation Patents: Intellectual property can be secured for new or improved formulations of mesna, such as:
  • Enhanced Stability: Formulations designed to reduce oxidation of the mercapto group, increasing shelf life.
  • Improved Bioavailability: Oral formulations designed for better absorption.
  • Novel Delivery Systems: Innovations in injectable formulations for sustained release or specific administration routes.
• Synthesis Process Patents: While the general synthesis is old, patents can be obtained for:
  • Novel Synthesis Routes: More efficient, cost-effective, or environmentally friendly methods of producing mesna API.
  • Purification Techniques: Improved methods for removing specific impurities, such as the disulfide dimer, to achieve higher API purity.
  • Polymorphs and Crystal Forms: Discovery and patenting of specific crystalline forms of mesna that may offer improved stability or manufacturing characteristics.

Notable Patent Holders and Their Focus:

• Baxter International: Patents related to mesna formulations for injection, including specific buffered solutions and methods of administration.
• Medac GmbH: Holds patents for various mesna formulations, including oral forms and potentially combinations designed for enhanced efficacy or patient compliance.
• Roche: While historically involved in chemotherapy, Roche has patents related to the adjunctive use of mesna with its own oncology products, such as ifosfamide.
• Generic Manufacturers: Companies like Aurobindo Pharma focus on process patents for efficient API production and may also develop novel generic formulations that can be patent-protected until expiry.

The patent landscape for mesna is mature, with the foundational patents on its basic synthesis and primary use having long expired. However, ongoing innovation in formulation and specific therapeutic applications continues to generate new intellectual property, offering opportunities for differentiation and market exclusivity.

How Does the Regulatory Environment Impact Mesna Supply?

The supply of mesna is heavily influenced by stringent regulatory requirements for pharmaceutical manufacturing and marketing. Regulatory bodies like the FDA, EMA, and others worldwide set standards that impact production, quality control, and market access.

Key Regulatory Considerations:

• Good Manufacturing Practices (GMP): All facilities involved in the manufacturing of mesna API and finished drug products must comply with current Good Manufacturing Practices (cGMP). This includes rigorous quality control, validation of processes, and documentation. Deviations can lead to product recalls, import alerts, and manufacturing shutdowns.
• Drug Master Files (DMFs) and Active Substance Master Files (ASMFs): API manufacturers must maintain detailed DMFs or ASMFs that are submitted to regulatory agencies. These files contain confidential, detailed information about the manufacturing process, facilities, and quality control of the API. Drug product manufacturers reference these filings in their marketing authorization applications.
• Marketing Authorization Applications (MAAs) / New Drug Applications (NDAs) / Abbreviated New Drug Applications (ANDAs): Companies seeking to market mesna products must obtain approval from the relevant regulatory authorities. For generic versions, an ANDA requires demonstrating bioequivalence to the reference listed drug.
• Pharmacopoeial Standards: Mesna must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs define purity, identity, assay, and impurity limits.
• Inspections and Audits: Regulatory agencies conduct regular inspections of manufacturing facilities to ensure ongoing compliance with GMP and other regulations. Drug product manufacturers also conduct audits of their API suppliers to ensure the quality and reliability of their supply chain.
• Post-Market Surveillance: Manufacturers are required to monitor and report adverse events associated with their products. Regulatory agencies can take action based on post-market data, including requests for labeling changes or market withdrawal.

Impact on Supply Chain:

• Barriers to Entry: The high cost and complexity of meeting regulatory requirements create significant barriers for new entrants into the mesna API manufacturing market.
• Supply Chain Resilience: Regulatory compliance is critical for maintaining a stable supply. Any disruption due to non-compliance can have severe consequences for patient access to essential chemotherapy support.
• Global Harmonization: While regulations differ slightly across regions, there is a growing trend towards harmonization, which can simplify global market access but also requires adherence to the highest common standards.
• Inspection Readiness: Manufacturers must maintain a constant state of readiness for regulatory inspections, which can influence operational priorities and investment in quality systems.

The regulatory environment ensures the safety and efficacy of mesna products but also dictates the operational requirements and market dynamics for its suppliers.

What are the Global Market Dynamics and Pricing Trends for Mesna?

The global market for mesna is largely driven by the incidence of cancers treated with cyclophosphamide and ifosfamide, and the clinical adoption of mesna as a standard prophylactic agent. The market is characterized by a mix of branded and generic products, influencing pricing.

Market Drivers:

• Chemotherapy Use: The primary driver is the use of alkylating agents like cyclophosphamide and ifosfamide, which are mainstays in treating various cancers, including lymphomas, sarcomas, and breast cancer.
• Awareness and Guidelines: Increased awareness among oncologists and adherence to clinical guidelines that recommend mesna prophylaxis for high-dose chemotherapy regimens.
• Generic Competition: The availability of generic mesna products has significantly impacted pricing, making the treatment more accessible.
• Oncology Market Growth: The overall growth of the oncology market, fueled by an aging population and advancements in cancer treatment, indirectly supports demand for supportive care agents like mesna.

Pricing Trends:

• Genericization Impact: The introduction of generic mesna, particularly in injectable forms, has led to substantial price reductions compared to originator products.
• Geographic Variations: Pricing can vary significantly by region due to differing market access policies, reimbursement rates, and the presence of local manufacturers. For example, pricing in North America and Europe may differ from that in emerging markets.
• Formulation Differences: Oral formulations, which may involve more complex manufacturing or proprietary excipients for improved patient compliance, can command higher prices than standard injectable solutions.
• Volume-Based Discounts: Large hospital systems and procurement groups often negotiate volume-based discounts, which can influence the effective price paid.
• API Cost Fluctuations: While mesna synthesis is established, fluctuations in raw material costs or increased regulatory compliance expenses for API manufacturers can indirectly impact finished product pricing.

Market Size and Growth:

Precise market size figures for mesna are not typically publicly detailed as it is often categorized within broader urology or supportive care markets. However, estimates place the global mesna market in the range of hundreds of millions of U.S. dollars annually. The market is expected to experience steady growth, in line with the global oncology drug market, with a compound annual growth rate (CAGR) in the low single digits. Growth in emerging markets, where access to chemotherapy is expanding, is likely to be a key contributor.

Competitive Landscape:

The competitive landscape for mesna API is relatively consolidated, with a few key players dominating supply. The finished dosage form market is more fragmented, with generic manufacturers competing alongside established pharmaceutical companies. Companies that can ensure consistent quality, regulatory compliance, and competitive pricing are best positioned. Innovations in oral formulations or combination therapies could offer future market differentiation.

Key Takeaways

• The mesna supply chain is controlled by a limited number of global API manufacturers, with Aurobindo Pharma and Medac GmbH being significant players.
• Production involves well-established chemical synthesis routes with purification challenges related to disulfide dimer formation.
• Intellectual property is concentrated on therapeutic uses and novel formulations rather than basic synthesis.
• Stringent regulatory compliance (GMP, DMFs) is essential for all mesna suppliers, creating high barriers to market entry.
• The market dynamics are shaped by generic competition, which has driven down prices, and the overall growth of the oncology sector.

Frequently Asked Questions

What are the primary risks associated with mesna API supply?

Risks include regulatory non-compliance leading to manufacturing halts or product recalls, supply chain disruptions due to geopolitical events or raw material shortages, and quality control failures that compromise API purity, particularly the formation of disulfide dimers.

How do different mesna formulations (injection vs. oral) impact supplier selection?

Supplier selection depends on the desired formulation. Injectable mesna requires sterile manufacturing capabilities and aseptic processing. Oral formulations demand expertise in granulation, tablet compression, or powder filling, alongside excipient compatibility testing and bioavailability enhancement.

What due diligence is critical when selecting a mesna API supplier?

Critical due diligence includes verifying current GMP certifications and regulatory inspection history (FDA, EMA, etc.), reviewing DMF/ASMF filings, assessing quality control procedures and impurity profiling capabilities, evaluating supply chain reliability and contingency plans, and understanding pricing structures and long-term supply agreements.

Are there any emerging technologies in mesna synthesis or formulation?

While mesna synthesis is mature, research may focus on continuous manufacturing processes for improved efficiency and consistency, or novel drug delivery systems for oral mesna to enhance absorption or reduce variability. Development of fixed-dose combinations with chemotherapeutic agents could also represent an area of innovation.

What is the typical shelf life of mesna API and finished products?

Mesna API, when stored under appropriate conditions (e.g., protected from light and air), typically has a shelf life of two to three years. Finished injectable mesna solutions usually have a shelf life of 24 to 36 months, depending on the specific formulation and packaging. Oral formulations' shelf life varies based on excipients and stability studies.

Citations

[1] Baxter International Inc. (n.d.). Mesna Injection. Retrieved from [Manufacturer's product information, specific URL not provided for general context]

[2] Medac GmbH. (n.d.). MESNA. Retrieved from [Manufacturer's product information, specific URL not provided for general context]

[3] Aurobindo Pharma Ltd. (n.d.). API Products. Retrieved from [Manufacturer's product information, specific URL not provided for general context]

[4] Fresenius Kabi. (n.d.). Mesna Injection. Retrieved from [Manufacturer's product information, specific URL not provided for general context]

[5] U.S. Food and Drug Administration. (2024). Drug Master Files: Overview. Retrieved from [FDA official website, specific URL not provided for general context]

[6] European Medicines Agency. (2024). Active Substance Master File (ASMF) procedure. Retrieved from [EMA official website, specific URL not provided for general context]

[7] United States Pharmacopeia. (2024). USP Monograph: Mesna. Retrieved from [USP official website, specific URL not provided for general context]